Why the study?
Does aspirin plus edoxaban reduce bleeding or restenosis compared to aspirin plus clopidogrel in patients with peripheral artery disease undergoing femoropopliteal EVT?
Population
203 patients who underwent femoropopliteal endovascular treatment. Edoxaban group: mean age 68.0±10.4 years…
Comparison
Aspirin plus edoxaban for 3 months vs Aspirin plus clopidogrel for 3 months
Design
RCT, randomized
Follow-up
6 months
Authors
Loading...
Comparable bleeding and restenosis rates do not support regimen change after femoropopliteal EVT; leaves open modest differences for larger trials.
Does aspirin plus edoxaban reduce bleeding or restenosis compared to aspirin plus clopidogrel in patients with peripheral artery disease undergoing femoropopliteal EVT?
In patients undergoing femoropopliteal EVT, edoxaban plus aspirin had similar bleeding risks and non-significantly lower restenosis rates compared to dual antiplatelet therapy, warranting larger trials.
Moll et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: